title: Trastuzumab in early-stage breast cancer: the question of treatment timing.
authors.affiliation: Research Centre for Pharmaceutical Care and Pharmacoeconomics, Katholieke Universiteit Leuven, Leuven, Belgium. steven.simoens@pharm.kuleuven.be
authors.forename: Steven
authors.initials: S
authors.lastname: Simoens
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000191:economics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D013997:Time Factors; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab
references.citation: Health Policy. 2008 Aug;87(2):146-59
references.pmid: 18164510
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7811-9
references.pmid: 16258083
references.citation: Ann Oncol. 2007 Sep;18(9):1493-9
references.pmid: 17761705
references.citation: N Z Med J. 2007 Jun 15;120(1256):U2593
references.pmid: 17589560
references.citation: Pharmacoeconomics. 2007;25(5):429-42
references.pmid: 17488140
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: Pharmacoeconomics. 2008;26(8):699-719
references.pmid: 18620462
references.citation: Pharmacoeconomics. 2007;25(3):181-5
references.pmid: 17335304
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: Lancet. 2008 May 17;371(9625):1644-6
references.pmid: 18486727
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references.pmid: 18250349